Everbeat was founded in 2016 by two cardiologists at the University of Pittsburgh, Matthew Jones, MD, and G. Stuart Mendenhall, MD, who saw an opportunity to improve the treatment of patients with cardiac arrhythmias. The doctors developed an engineering prototype and discovered that accurate dry-electrode recordings of the heart were possible. They filed patents for devices and algorithms to support this opportunity and received competitive seed funding from the university.
The university decided to commercialize this technology through the Pitt Innovation Institute and formed a Virginia-based LLC called Grektek. The original management team purchased the assets of a mobile health software firm, and its president, Greg Eoyang, became everbeat’s Chief Technology Officer, continuing in this role in product development. Former BlackRock executive John McCauley joined everbeat in early 2017 as Chief Executive Officer, and the company adopted ‘everbeat’ as its brand name.
Everbeat has been developing wearable cardiac devices for five years, along with complementary applications that allow patients to view and manage their health data. This includes a physician portal where doctors can monitor their patients.
Working with a Brooklyn-based product development partner, everbeat completed development of the prototype everbeat ring in late 2021. Recognizing the importance of more focus on the venture, Dr. Matthew Jones assumed the CEO role from January 2022 until November 2024. For continuity, John remains engaged as an advisor to the firm.
G. Stuart Mendenhall, MD, now leads the everbeat team, implementing the everbeat ring plan for FDA clearance and introducing the everbeat as a novel, profoundly important medical-grade monitor of cardiac health. In 2025 we will bring the everbeat ring to market, along with an everbeat patch that can be used to provide important supplemental ECG data. We are expanding our management team and our core board of directors to lead the company into its exciting future.
Everbeat’s mission is to improve cardiac care through efficient and accurate health monitoring, enabling the early detection and prevention of heart disease. Using everbeat technology, our patients gain insights into their heart performance and overall health. The everbeat ring is currently focused on arrhythmia characterization, and we also offer, and will continue refining, systems for monitoring overall heart health and ischemia (lack of blood flow).
Predict. Prevent. Empower.
We have designed the everbeat ring to be sleek and simple for patients to use.
The electrocardiogram (ECG) is an incredibly powerful diagnostic tool, and the everbeat ring allows patients to record many different types of clinical-grade ECG lead areas. This information, when analyzed through our traditional and artificial intelligence (AI) algorithms, can provide critical feedback to both patients and physicians. Everbeat technology can detect arrhythmic events earlier than the onset of symptoms, potentially preventing serious or debilitating events like stroke or heart attack.
At everbeat, we build technology—starting with the everbeat ring-based platform—that makes it easy for patients and physicians to manage heart health more effectively.
Pure connected health, on your finger.
